The LDT Final Rule: Diagnostic Companies Have Until 2028 to Restructure

← Back to All Insights

FDA's May 2024 Final Rule on Laboratory-Developed Tests ended a 35-year period of enforcement discretion. Diagnostic developers and the clinical laboratories that run their tests now operate under a phaseout schedule that brings most LDTs under the same regulatory framework as commercial IVDs by 2028. The structural change reshapes diagnostic company business models in ways that diligence has not fully absorbed.

Many diagnostic companies built their commercial strategy around the LDT pathway because it allowed market entry without FDA premarket clearance. That door is closing on a specific schedule.

The Phaseout Schedule

The Final Rule phases enforcement discretion out in five stages between 2025 and 2028: Stage 1 (May 2025) — Medical Device Reporting requirements; Stage 2 (May 2026) — Registration, listing, and labeling; Stage 3 (May 2027) — Quality System Requirements; Stage 4 (Nov 2027) — Premarket review for high-risk (Class III) LDTs; Stage 5 (May 2028) — Premarket review for moderate-risk (Class II) LDTs. Each stage adds compliance cost and capability requirements.

The Enforcement Discretion Carve-Outs

FDA preserved enforcement discretion for several categories: LDTs first marketed before May 6, 2024 (grandfathered with some limits), LDTs developed and used within an integrated healthcare system, LDTs that are 1976 Type tests, and LDTs for unmet needs where no FDA-cleared equivalent exists. These carve-outs are narrower than they appear and depend on specific definitional criteria diligence often misreads.

Cost Impact on Laboratory Developers

Bringing an LDT through FDA premarket review costs $500K-$3M per test depending on classification. Maintaining QSR compliance adds $200K-$800K in annual infrastructure overhead. Smaller diagnostic developers running 5-15 LDTs face a multi-million-dollar compliance buildout on a fixed timeline. Some will pass; some will exit categories that no longer pencil out.

Strategic Responses

Diagnostic developers are responding through several strategies: pursuing 510(k) or De Novo clearance for their highest-margin tests; partnering with established IVD manufacturers to license tests onto cleared platforms; consolidating their LDT portfolio into the highest-value tests; or exiting markets where compliance economics no longer work. The Pareto distribution of diagnostic developer responses is concentrated.

Implications for Therapeutics Sponsors

Therapeutics that depended on widely available LDT testing for patient identification now face narrower diagnostic pipelines. A drug with a single FDA-cleared companion diagnostic and widespread LDT alternatives in 2024 may have only the single FDA-cleared option by 2028. This affects launch dynamics, payer access, and commercial uptake.

Diligence Questions

For diagnostic company investors: which of the target's tests fall into preserved enforcement discretion categories? What is the planned regulatory path for tests that do not? Has the company budgeted the QSR buildout and FDA submission costs against its current capital plan? What is the risk that key tests fail to clear or face withdrawal post-2028?

The LDT Final Rule is not a future regulatory threat—it is a current, enforceable rule with stage-specific compliance deadlines. Diagnostic company business models that depended on indefinite enforcement discretion are operating on borrowed time. Investors and acquirers should treat the 2028 milestone as a hard event in their financial models, not a soft regulatory drift.